Blincyto (Blinatumomab) is used for the treatment of patients with acute lymphoblastic leukemia (ALL).

BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adults and children with (1) B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. This indication is approved under accelerated approval based on MRD response rate and hematological relapse-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (2) Relapsed or refractory B-cell precursor acute lymphoblastic leukemia

You can order Blincyto (Blinatumomab) from Indian Pharma Network, New Delhi. India if the drug has not been approved or is not available in your country.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India.

For procurement cost of Blincyto (Blinatumomab) in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Blincyto (Blinatumomab) medicine price list or cost in India.

The order for Blincyto (Blinatumomab) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Blinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.
In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program.
The benefits of treating R/R B-cell precursor ALL patients with blinatumomab include increased overall survival, more favorable hematologic remission and molecular response rates, and a lower incidence rate of selected adverse events when compared with standard-of-care chemotherapy.

BLINCYTO®(blinatumomab) for injection, for intravenous use. Initial U.S. Approval: 2014

Generic Name: blinatumomab

For injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution

Blincyto (blinatumomab)

GET IN TOUCH
with Indian Pharma Network

Indian Pharma Network, Delhi provides access to BLINCYTO (Blinatumomab) on the Named Patient Import basis in India.

Blincyto (Blinatumomab)

Dosage Forms and Strengths For More Details

FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse For More Details

Blinatumomab Approved in Europe for MRD+ ALL For More Details

Blincyto (Blinatumomab) manufacturer and suppliers in India

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Blincyto (Blinatumomab) on prescription and Import License in Patient's Name only.

For overseas patients, Blincyto (Blinatumomab) can be made available in Send your enquiry to find Blincyto (Blinatumomab) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.

Steps to access BLINCYTO (Blinatumomab) on the Named Patient Import basis.

Step 1.
You send a request for your medicine online:-
Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.

Step 2.
We verify your prescription and medical details:-
Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.

Step 3.
We source your medicine:-
Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 4.
We deliver your medicine:-
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Documentation for Named-Patient import to access Blincyto (Blinatumomab).

Doctor’s Prescription –
We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

Room temperature shipping

For this medication, standard shipping applies. This means that a consistent room temperature of 15 to 25°C is maintained during transit.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

IPN, Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified professionals of pharmaceutical Industry. Registration Number :07AAFFI2544E1ZO under GST Act. Specialized in Oncology Pharmacy. Helped more than 6,000 patients.

Helps you access to a FDA approved medicines, no matter where you live. Sourcing each medicine for named patient use and overseeing every aspect of the shipping, customs and delivery.

IPN, New Delhi a trusted pharmaceutical exporter and wholesaler for Anti-Cancer Medicines in India.
Branch Office in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jodhpur